The therapeutic landscape has never been more complex. As the pharmaceutical industry advances beyond traditional small molecules into biologics, oligonucleotides, and cell therapies, the specialized expertise required to characterize these diverse modalities has grown exponentially. AstraNova BioLabs has invested strategically in people, platforms, and methods to serve this expanding modality landscape with equal depth and rigor.
Tell us whether you are advancing a small molecule, biologic, peptide, oligonucleotide, or cell therapy. We will align the assays to the modality-specific decision points.
Small molecules remain the dominant therapeutic modality in modern drug discovery. AstraNova's integrated small molecule platform encompasses the full discovery cascade from biochemical target profiling to in vitro ADME/Tox characterization, providing comprehensive data to guide medicinal chemistry decisions and regulatory submissions.
Monoclonal antibodies, bispecifics, antibody-drug conjugates, and therapeutic proteins require specialized characterization approaches. AstraNova's biologics platform delivers the binding kinetics, functional characterization, and mechanism-of-action data that biologic programs demand.
Therapeutic peptides occupy a unique space between small molecules and biologics, combining favorable target engagement with synthetic accessibility. Our peptide pharmacology platform characterizes the receptor pharmacology, stability, and functional activity of peptide drug candidates across major therapeutic classes.
ASOs, siRNAs, saRNAs, and mRNA therapeutics demand specialized target engagement and delivery characterization platforms. AstraNova provides mechanistic evaluation of oligonucleotide programs with cellular systems validated for the specific modality class.
CAR-T, CAR-NK, TCR-T therapies, and viral gene delivery vectors represent the frontier of transformative medicine. AstraNova's specialty biology team provides functional characterization, target engagement, and safety profiling platforms tailored to the unique demands of advanced cell and gene therapy programs.
Bring us the program question, constraints, and next decision point. We will map the right assays, controls, timeline, and reporting package before the first plate is run.
